Excitement builds for ISTH 2025 Congress in Washington, D.C. as late-breakthrough abstracts are announced

CHAPEL HILL, N.C., June 12, 2025 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH) prepares to welcome nearly 5,000 attendees from the global thrombosis and hemostasis community to the ISTH 2025 Congress in Washington, D.C.

A key highlight of the ISTH 2025 Congress, taking place from June 21-25, 2025, is the presentation of late-breakthrough abstracts, offering new data from major clinical trials and breakthrough studies, giving attendees a first look at transformative findings.

The following late-breakthrough abstracts will be highlighted in one session on Sunday, June 22, from 9:30-10:45 a.m. in Ballroom A-C of the Walter E. Washington Convention Center:

• Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Acute Venous Thromboembolism: Lana Castellucci, M.D., Ottawa Hospital Research Institute, University of Ottawa, Canada
• Phase 3 Study of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia A: Robert Sidonio, M.D., Department of Pediatrics Emory University School of Medicine, United States
• Promoting the thrombosis-induced Alox15 pathway for the treatment of sepsis-induced lung injury: Colin Evans, Ph.D., University of South Carolina School of Medicine, United States
• VELORA Pioneer: first-in-human safety and PK/PD study of HMB-002 in Type 1 "Von Willebrand disease": Priyanka Raheja, M.D., The Royal London Hospital Haemophilia Centre Barts Health NHS Trust, United Kingdom
• Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura: Paul Coppo, M.D., Ph.D., Department of Hematology and National Reference Center for Thrombotic Microangiopathies Hôpital Sai, France

Full details of late-breakthrough abstracts are embargoed until the day and time of presentation.

"I'm thrilled that the ISTH 2025 Congress will soon convene in Washington, D.C. with many of the brightest minds in the thrombosis and hemostasis community," said Guy Young, M.D., Chair of the ISTH 2025 Annual Congress Planning Committee. "Attendees will enjoy a world-class scientific program and Congress experience that will inspire collaboration and innovation."

All Congress abstracts are available online. In addition to a robust scientific program, the ISTH 2025 Congress will also offer a vibrant industry exhibition showcasing the latest innovations in diagnostics, therapeutics and other related solutions and products available to scientists and physicians to advance research and patient care.

Members of the press are invited to register for a complimentary ISTH 2025 press registration here. For more information, visit the ISTH 2025 Virtual Press Room. For information on the overall Congress, visit: www.isth2025.org.

About the ISTH

Founded in 1969, the ISTH is the leading international medical and scientific professional organization dedicated to advancing the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and hemostasis. The ISTH professional membership community includes more than 7,000 clinicians, researchers and educators from more than 120 countries working together to advance science and improve clinical care around the world. Among its highly-regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, clinical and laboratory practice guidance and guidelines, peer-reviewed publications, expert committees and World Thrombosis Day on 13 October. Learn more at www.isth.org.

SOURCE International Society on Thrombosis and Haemostasis